PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (PTCT) Stock Overview
Explore PTC Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
5.7B
P/E Ratio
8.31
EPS (TTM)
$8.60
ROE
-3.62%
PTCT Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of PTC Therapeutics, Inc. (PTCT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 39.43, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $87.06.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 8.31 and a market capitalization of 5.7B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.